Irit Gliko-Kabir
Hoofd Techniek/Wetenschap/O&O bij BIOLINERX LTD.
Actieve functies van Irit Gliko-Kabir
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
BIOLINERX LTD. | Hoofd Techniek/Wetenschap/O&O | 01-09-2017 | - |
Loopbaan van Irit Gliko-Kabir
Eerdere bekende functies van Irit Gliko-Kabir
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Hoofd Techniek/Wetenschap/O&O | 01-07-2014 | - |
Opleiding van Irit Gliko-Kabir
The Hebrew University of Jerusalem | Doctorate Degree |
Statistieken
Internationaal
Israël | 4 |
Operationeel
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 1 |
Graduate Degree | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
BIOLINERX LTD. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Bioblast Pharma Ltd.
Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Beurs
- Insiders
- Irit Gliko-Kabir
- Ervaring